Adjuvant-dependent innate and adaptive immune signatures of risk of SIV(mac251) acquisition

A recombinant vaccine containing Aventis Pasteur’s canarypox vector (ALVAC)–HIV and gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution of alum with the more immunogenic MF59 adjuvant is under consideration for the next efficacy human trial. We found here th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Med
Main Authors: Vaccari, Monica, Gordon, Shari N, Fourati, Slim, Schifanella, Luca, Liyanage, Namal P M, Cameron, Mark, Keele, Brandon F, Shen, Xiaoying, Tomaras, Georgia D, Billings, Erik, Rao, Mangala, Chung, Amy W, Dowell, Karen G, Bailey-Kellogg, Chris, Brown, Eric P, Ackerman, Margaret E, Vargas-Inchaustegui, Diego A, Whitney, Stephen, Doster, Melvin N, Binello, Nicolo, Pegu, Poonam, Montefiori, David C, Foulds, Kathryn, Quinn, David S, Donaldson, Mitzi, Liang, Frank, Loré, Karin, Roederer, Mario, Koup, Richard A, McDermott, Adrian, Ma, Zhong-Min, Miller, Christopher J, Phan, Tran B, Forthal, Donald N, Blackburn, Matthew, Caccuri, Francesca, Bissa, Massimiliano, Ferrari, Guido, Kalyanaraman, Vaniambadi, Ferrari, Maria G, Thompson, DeVon, Robert-Guroff, Marjorie, Ratto-Kim, Silvia, Kim, Jerome H, Michael, Nelson L, Phogat, Sanjay, Barnett, Susan W, Tartaglia, Jim, Venzon, David, Stablein, Donald M, Alter, Galit, Sekaly, Rafick-Pierre, Franchini, Genoveffa
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916782/
https://ncbi.nlm.nih.gov/pubmed/27239761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4105
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados